The invention relates to the technical field of biological medicines, in particular to FcRL2 as a serum marker or
cerebrospinal fluid marker for early diagnosis, screening and
typing detection of neurosyphilis patients. The FcRL2
protein is one of
receptor superfamily members,
Fc receptor-like glycoproteins, and is related to immune response regulation and immune
cell functions. According to the invention, the concentration of the FcRL2
protein in serum or
cerebrospinal fluid is used as an index for early diagnosis of neurosyphilis,
typing detection of symptomatic neurosyphilis,
asymptomatic neurosyphilis, neurosyphilis and recessive
syphilis, evaluation of
nerve injury degree and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening,
typing and
nerve injury evaluation of the neurosyphilis. Compared with the prior art, the FcRL2 not only has high sensitivity, but also can diagnose the neurosyphilis through noninvasive serum detection, and is beneficial to diagnosis and management of the neurosyphilis in
community hospitals and local hospitals.